Eurekalert
30.10.2024
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, announced a milestone achieved in the multi-year research collaboration with Sanofi. Following the agreement in November 2022, the collaboration yielded an AI-facilitated lead with first-in-class (FIC) potential against an undruggable transcription factor target for treating oncology diseases, enhanced by Insilico Medicine’s AI platform, Pharma.AI.
Eurekalert
21.11.2024
On November 20th, the renowned business magazine Fortune released its 2024 Fortune 50 AI Innovators list, highlighting the AI companies leading in the new phase of AI technology applications. Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to be listed. Other honorees include internet giants , leading companies in the chip industry and AI emerging stars.
Eurekalert
22.11.2024
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors. The achievement marks the 10th AI-driven molecule self-developed by Insilico to be recognized with clearance to enter clinical trials.
Insilico Medicine Wechat Post
13.12.2024
Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced that it has received the first clinical milestone payment of $10 million for XL309 (previously known as ISM3091) from Exelixis.
Disclaimer
Investment Involves risk. Past performance does not represent future performance. Investor should read the product’s Prospectus for details and risk factors before making investment decision. The contents of this website is prepared and maintained by Mirae Asset Capital (China) Limited. This material has not been reviewed by the Securities and Futures Commission.
Nov 30, 2024
